Outcome

This study demonstrates that Hyperbaric Oxygen Therapy (HBOT) at 150 kPa for 40 sessions significantly improves symptoms and cognitive functions in individuals with persistent postconcussion syndrome (PPCS) and PTSD following mild traumatic brain injury. Notable improvements were observed in memory depression anxiety sleep quality and overall quality of life with benefits persisting for two months post-treatment.

Introduction

Persistent post-concussion syndrome (PPCS) following a mild traumatic brain injury (mTBI) poses significant challenges especially within civilian and military populations. Conventional treatment options are limited and often ineffective. In this context hyperbaric oxygen therapy (HBOT) emerges as a promising intervention. This study aimed to evaluate the efficacy of HBOT in alleviating symptoms associated with PPCS and PTSD in individuals with mTBI.

In a randomized controlled trial involving sixty-three participants the study compared the effects of forty sessions of HBOT at 150 kPa each lasting 60 minutes and administered once daily over eight weeks against a no-treatment control group. The HBOT group demonstrated notable improvements in neurobehavioral symptoms memory cognitive functions depression anxiety sleep quality and overall quality of life. These benefits persisted even two months post-treatment. After the control group received HBOT treatments in a crossover design they experienced similar significant improvements affirming the therapy’s efficacy.

These findings underscore HBOT’s potential as a viable therapeutic option offering sustained relief from PPCS and PTSD symptoms and improving the overall quality of life for individuals with mTBI.

Results

The study conducted a randomized controlled trial involving sixty-three civilian and military participants with mild traumatic brain injury (mTBI) and Persistent Post-Concussion Syndrome (PPCS). Participants were divided into two groups: one received 40 sessions of Hyperbaric Oxygen Therapy (HBOT) at 150 kPa for 60 minutes each administered daily over eight weeks while the control group did not receive any treatment during this period.

Significant improvements were documented in the HBOT group compared to the control group across several key measures. The HBOT group exhibited enhanced neurobehavioral symptoms as evidenced by better scores on the Neurobehavioral Symptom Inventory. Cognitive function improvements were demonstrated through elevated Memory Index and Automated Neuropsychological Assessment Metrics scores. Additionally there were marked reductions in depression and anxiety levels reflected in the Hamilton Depression and Hamilton Anxiety Scales.

The study also found substantial improvements in PTSD symptoms measured by the Post-Traumatic Stress Disorder Checklist. Participants reported better sleep quality assessed through the Pittsburgh Sleep Quality Index and an enhanced overall quality of life reflected in Quality of Life after Brain Injury scores. Notably when the control group later received HBOT in a crossover phase they experienced similar positive outcomes.

These benefits persisted at least two months post-treatment indicating sustained efficacy. Both groups continued showing improvements during this follow-up period reinforcing the long-term potential of HBOT. This suggests that HBOT at 150 kPa not only ameliorates symptoms of PPCS and PTSD but also promotes lasting enhancements in memory cognitive functions mood sleep quality and overall quality of life for individuals with mTBI/PPCS.

Conclusion

In conclusion this study underscores the promising effects of Hyperbaric Oxygen Therapy (HBOT) on individuals with persistent post-concussion syndrome (PPCS) and post-traumatic stress disorder (PTSD) following mild traumatic brain injury (mTBI). The research demonstrated that 40 sessions of HBOT at 150 kPa significantly improved neurobehavioral symptoms memory cognitive functions depression anxiety sleep quality and overall quality of life. These improvements were consistent across both the initial HBOT group and the control group after crossover to HBOT with benefits persisting for at least two months post-treatment.

The significance of these findings is substantial within the scope of HBOT research providing compelling evidence for its efficacy as a therapeutic intervention for mTBI-related conditions. By yielding sustained enhancements in both mental health and cognitive capabilities HBOT presents a viable treatment option that could be integrated into neurorehabilitation programs for individuals suffering from long-term effects of brain injuries.

Future research should aim to replicate these results in larger more diverse populations to validate the therapy’s broad applicability. Additionally investigating the underlying mechanisms through which HBOT facilitates these improvements could further optimize treatment protocols and solidify its place within clinical practice. This study sets a strong foundation for further exploration into HBOT reinforcing its potential to significantly improve the lives of those afflicted by PPCS and PTSD.